Wonodi Chizoba, Farrenkopf Brooke Amara
International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA.
Vaccines (Basel). 2023 Sep 28;11(10):1543. doi: 10.3390/vaccines11101543.
While there is a coordinated effort around reaching zero dose children and closing existing equity gaps in immunization delivery, it is important that there is agreement and clarity around how 'zero dose status' is defined and what is gained and lost by using different indicators for zero dose status. There are two popular approaches used in research, program design, and advocacy to define zero dose status: one uses a single vaccine to serve as a proxy for zero dose status, while another uses a subset of vaccines to identify children who have missed all routine vaccines. We provide a global analysis utilizing the most recent publicly available DHS and MICS data from 2010 to 2020 to compare the number, proportion, and profile of children aged 12 to 23 months who are 'penta-zero dose' (have not received the pentavalent vaccine), 'truly' zero dose (have not received any dose of BCG, polio, pentavalent, or measles vaccines), and 'misclassified' zero dose children (those who are penta-zero dose but have received at least one other vaccine). Our analysis includes 194,829 observations from 82 low- and middle-income countries. Globally, 14.2% of children are penta-zero dose and 7.5% are truly zero dose, suggesting that 46.5% of penta-zero dose children have had at least one contact with the immunization system. While there are similarities in the profile of children that are penta-zero dose and truly zero dose, there are key differences between the proportion of key characteristics among truly zero dose and misclassified zero dose children, including access to maternal and child health services. By understanding the extent of the connection zero dose children may have with the health and immunization system and contrasting it with how much the use of a more feasible definition of zero dose may underestimate the level of vulnerability in the zero dose population, we provide insights that can help immunization programs design strategies that better target the most disadvantaged populations. If the vulnerability profiles of the truly zero dose children are qualitatively different from that of the penta-zero dose children, then failing to distinguish the truly zero dose populations, and how to optimally reach them, may lead to the development of misguided or inefficient strategies for vaccinating the most disadvantaged population of children.
虽然各方正在协同努力实现零剂量儿童数量归零,并消除免疫接种服务中现有的公平差距,但明确“零剂量状态”的定义以及使用不同的零剂量状态指标会有哪些得失,这一点很重要。在研究、项目设计和宣传中,有两种常用的方法来定义零剂量状态:一种是使用单一疫苗作为零剂量状态的替代指标,另一种是使用一组疫苗来识别未接种所有常规疫苗的儿童。我们利用2010年至2020年最新公开的人口与健康调查(DHS)和多指标类集调查(MICS)数据进行了一项全球分析,以比较12至23个月大的“五价疫苗零剂量”(未接种五价疫苗)、“真正”零剂量(未接种任何剂量的卡介苗、脊髓灰质炎疫苗、五价疫苗或麻疹疫苗)以及“误分类”零剂量儿童(五价疫苗零剂量但至少接种了一剂其他疫苗)的数量、比例和特征。我们的分析涵盖了来自82个低收入和中等收入国家的194,829份观察数据。全球范围内,14.2%的儿童为五价疫苗零剂量,7.5%为真正零剂量,这表明46.5%的五价疫苗零剂量儿童至少与免疫接种系统有过一次接触。虽然五价疫苗零剂量儿童和真正零剂量儿童的特征存在相似之处,但真正零剂量儿童和误分类零剂量儿童在关键特征比例上存在关键差异,包括获得母婴保健服务的情况。通过了解零剂量儿童与卫生和免疫接种系统可能存在的联系程度,并将其与使用更可行的零剂量定义可能低估零剂量人群脆弱性水平的情况进行对比,我们提供了一些见解,有助于免疫接种项目制定更好地针对最弱势群体的策略。如果真正零剂量儿童的脆弱性特征与五价疫苗零剂量儿童在质上不同,但未能区分真正零剂量人群以及如何以最佳方式覆盖他们,可能会导致为最弱势儿童群体制定错误或低效的疫苗接种策略。